In CD8+ cells isolated from peripheral blood of tumor patients, the TLR2 agonist Pam3Csk4 enhanced the cytolytic activation of peripheral and tumor-infiltrating CD8+ T cells from GCs (18). Here, TLR2 is linked to neoplasm.